TITLE

PDT Outcomes Show Promise at Two Years

PUB. DATE
April 2001
SOURCE
Review of Ophthalmology;Apr2001, Vol. 8 Issue 4, p107
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Suggests that photodynamic therapy with verteporfin can safely reduce the risk of vision loss in patients with subfoveal choroidal neo-vascularization caused by age-related macular degeneration. Clinical trials at 22 opthalmic practices in Europe and North America; Outcome of the treatment after the first and second year.
ACCESSION #
4362991

 

Related Articles

  • SARcode T-Cell Inhibitor Shows Positive Results.  // Review of Ophthalmology;Jun2011, Vol. 18 Issue 6, p9 

    The article reports on SARcode Corp.'s Phase II dry-eye trial of its lead investigational molecule SAR 1118, in which the subjects who receive the treatment have demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function in Brisbane, California.

  • Technique Effective For Therapeutic Ptosis. M., Mulhern; Rootman, D.; Fraunfelder, F.; Rich, L.; Diestelhorst., M.; Grisanti, S.; Papa, V.; Milazzo, G.; Santocono, M.; Servolle, V.; Flanagan, Lee J. // Review of Ophthalmology;May2002, Vol. 9 Issue 5, p118 

    Presents several techniques for therapeutic ptosis. Use of stamler lid splint in treating a variety of ocular surface disorders; Effectiveness of photodynamic therapy to control postoperative fibrosis in glaucomatous eyes; Management of inflammation after uneventful phacoemulsification and...

  • Fixed-Combination Drugs In Glaucoma Treatment.  // Review of Ophthalmology;Aug2006, Vol. 13 Issue 8, p70 

    The article presents an activity for ophthalmologists regarding fixed-combination drugs in glaucoma treatment. Clinical findings of the treatment are incorporated with doctor patient experiences. It aims to describe the benefits of fixed-combination glaucoma drugs, and describe the efficacy of...

  • Results Due in Phase II Dry - Eve Study.  // Review of Ophthalmology;Oct2011, Vol. 18 Issue 10, p9 

    The article reports on the completion of treatment and follow-up conducted by RegeneRx Biopharmaceuticals Inc. on 69 patients in its Phase II clinical trial on RGN-259 eye drops used for treating dry-eye syndrome.

  • Baseline demographics critical to PDT clinical trial. Charters, Lynda // Ophthalmology Times;8/1/2001, Vol. 26 Issue 15, p29 

    Discusses the importance of baseline demographics in a phase III clinical trial of SnET2 photodynamic therapy (PDT) to treat subfoveal choroidal neovascularization (CNV). Brief overview of PDT; Significant improvements seen from the first two phases of the trial; Demographic parameters studied.

  • Introduction of photodynamic therapy for the treatment of neovascular age-related macular degeneration: tracking a moving target. Foot, B; Foy, R; Chakravarthy, U; Wormald, R // Eye;Jul2003, Vol. 17 Issue 5, p583 

    Objectives To identify changes in referral and treatment patterns of neovascular age-related macular degeneration with photodynamic therapy (PDT) within ophthalmology units in NHS hospitals and assess how beliefs about what would constitute a worthwhile level of clinical benefit had altered over...

  • Lumigan: A New Approach to Managing IOP. Abelson, Mark B.; Chapin, Matthew J. // Review of Ophthalmology;Feb2001, Vol. 8 Issue 2, p58 

    Reports on the performance of a glaucoma medication called Lumigan in the Phase III United States Food and Drug Administration clinical trials. Review of a comparison of Lumigan and Latanoprost; Description of Lumigan; Safety and efficacy profile of Lumigan.

  • Preliminary Data Revealed for AzaSite Plus Trial.  // Review of Ophthalmology;Jan2009 Part 1 of 2, Vol. 15 Issue 1, p9 

    The article reports on the announcement by U.S.-based Insite Vision Inc. about preliminary results from its Phase III clinical trial of ISV-502, antibiotic for the treatment of blepharoconjunctivitis. Data from the Phase III trial will be used by the company in the finalization of a planned...

  • Into the Eye: Two New Ways to Deliver Drugs. Kent, Christopher // Review of Ophthalmology;Jan2010, Vol. 17 Issue 1, p16 

    The article reports on the new underdeveloped EGP 437 drug and EyeGate II iontophores drug delivery device to treat internal ocular problem. It mentions that the drug delivery programmable device uses electrochemical repulsion to push drugs to the sclera which allows the doctor to control the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics